Pimobendan: A Treatment for Preclinical Mitral Valve Disease in Dogs

Pimobendan has been used to treat symptomatic heart failure in dogs for years, but after a study showed that it delayed the onset of congestive heart failure in dogs with preclinical myxomatous mitral valve disease, it received conditional approval from the U.S. FDA to treat those cases. What does that mean for your patients? Learn more in this video.
Back to Top